Lili Anglister (Jerusalem, Israel)
Michael Aschner (New York, USA): Metals-induced cholinergic dysfunction and neurodegenerative disorders
Thomas Balle (Sydney, Australia): A Dynamic View on a4b2 nAChR Agonist and Modulator Binding
Maria Laura Bolognesi (Bologna, Italy): Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
Anita Bosak (Zagreb, Croatia) Evaluation of 4-aminoquinolines as potential anticholinesterase agents in the treatment of Alzheimer’s disease
David A. Brown (London, UK)
Jean-Pierre Changeux (Paris, France): From Nicotinic Receptor structure to Cognition and Covid19
A Claudio Cuello (Montreal, Quebec, Canada & Oxford, UK) The impact of a novel NGF metabolic pathway on the forebrain cholinergic system in health and in the Alzheimer’s pathology
Ezio Giacobini (Geneva, Switzerland): Rethinking Cholinergic Therapy for Alzheimer’s Disease
Fredrik Ekström (Umea, Sweden): On in situ Assembly of Choline Acetyltransferase Ligands
Abraham Fisher (Rehovot, Israel): Muscarinic stimulation of post-synaptic receptors for the potential treatment and prevention of cognitive decline
Ryan Hibbs (Dallas, Texas, USA): Structural insights into nicotinic receptor pharmacology, permeation and gating
Carrie K. Jones (Nashville, Tennessee, USA): Development of M5 NAM and orthosteric inhibitors for opioid use disorder
Svjetlana Kalanj Bognar (Zagreb, Croatia): Cell adhesion glycoprotein neuroplastin in human cognition and neurodegeneration
Zrinka Kovarik (Zagreb, Croatia): Butyrylcholinesterase role in cholinergic mechanisms analysed with new and well-known inhibitors
Claire Legay (Paris, France): Deciphering ColQ modes of action at the neuromuscular junction
Frank Longo (Stanford, California, USA)
Lin Mei (Cleveland, Ohio, USA): Novel mechanisms of neuromuscular junction assembly and disorders revealed by revisiting the classic adapter protein rapsyn
Nikolina Maček Hrvat (Zagreb, Croatia): Neuroprotection analysed with acetylcholinesterase reactivators
Pascale Marchot (Marseille, France): Molecular bases for partnership of the C. elegans ChE-like adhesion molecule, neuroligin-1, with punctin
Andreas Meisel (Berlin, Germany): Role of cholinergic pathways in the pathobiology of stroke
Cesare Montecucco (Padova, Italy): Inhibition of the binding of tetanus neurotoxin to peripheral cholinergic nerve terminals by human monoclonal antibodies: prophylaxis and therapy of tetanus
Dirk Montag (Magdeburg, Germany)
Kamil Musilek (Hradec Kralove, Czechia): Modification of oxime nucleophiles for enhanced reactivation of cholinesterases
Melissa Murray (Jacksonville, Florida, USA)
Florian Nachon (Brétigny sur Orge, France): Design and evaluation of novel reactivators of cholinesterases inhibited by nerve agents
Agneta Nordberg (Stockholm, Sweden): The role of alpha 7 nicotinic acetylcholine receptor in Alzheimer´s disease pathology and other proteinopathies
Kinji Ohno (Nagoya, Japan): Three newly identified molecules that facilitate the formation of neuromuscular junction
Sergej Pirkmajer (Ljubljana, Slovenia): Agrin signalling in human skeletal muscle cells
Marco Prado (London, Ontario, Canada): Cholinergic mechanisms in the brain: Relevance to Alzheimer’s pathology and cognitive deficits
Ines Primožič (Zagreb, Croatia): Modulating cholinesterases activity by quinuclidine and cinchona-based compounds
Konstantinos Poulas (Patras, Greece) COVID-19 and the nicotinic cholinergic pathway
Zoran Radić (La Jolla, California, USA): Insights into functionally relevant conformational flexibility of protein backbones in cholinesterase structures
Yvonne Rosenberg (Washington, USA): Inhaled butyrylcholinesterase prophylaxis and post-exposure RS194B oxime treatments for pulmonary exposure to organophosphate neurotoxins
R. Jane Rylett (London, Ontario, Canada): Impact of expression of 82-kDa ChAT on Alzheimer pathology in a mouse model
Hermona Soreq (Jerusalem, Israel): Seeking non-coding RNA controllers of acetylcholine signaling in health and disease
Taylor Schmitz (London, Ontario, Canada)
Jonathan Sussman (Manchester, UK)
Palmer Taylor (La Jolla, California, USA): Accessing the CNS for antidotal actions: optimizing an antidote transport inhibitor combination
Kevin J. Tracey (Manhasset, New York, USA)
Victor Tsetlin (Moscow, Russia): Venom components and synthetic analogs acting on nicotinic receptors and on other targets
Karl Tsim (Hong Kong, China)
Tamara Zorbaz (Jerusalem, Israel; Zagreb, Croatia)